Agilent Technologies Acquires ACEA Biosciences to Strengthen Platform and Capabilities in Cell Analysis

Shots:

• ACEA to receive $250M in upfront cash as a total deal value, adding a differentiated portfolio and organizational capabilities in cell analysis
• Agilent will get hold of ACEA’s CFDA and CE-IVD labelled cytometer configuration, i.e. NovoCyte flow cytometer and xCELLigence Real-Time Cell analyzer used for monitoring growth, function, and cellular responses of cells
• The acquisition will expand Agilent’s R&D, manufacturing & operations, and commercial capabilities and coverage in China

Click here to read full press release/ article | Ref: Agilent Technologies | Image: Pr web